News - GreenLight

Filter by year

Filter by topic

GreenLight Showcases Discovery and Developability Services at PEGS Europe 2019

Bespoke approach generates high affinity antibodies and selects lead candidates with the strongest chances of success in the clinic Cambridge, UK, 18 November 2019 – GreenLight is showcasing its Discovery and Developability Services, enabling biopharmaceutical companies to generate high affinity antibodies and select lead candidates with the highest chances of clinical success at the 11th Annual Protein […] Read more

Sonnet BioTherapeutics selects GreenLight as clinical stage manufacturing partner for its IL-12-FHAB cytokine-derived therapeutic candidate

PRINCETON, NJ and San Diego, CA, USA 22 October 2019 – Sonnet BioTherapeutics Inc., a clinical stage biopharmaceutical developing innovative targeted biologic drugs, announced today that it has selected GreenLight as its manufacturing partner for SON-1010, an IL-12-FHAB cytokine, in preparation for clinical development. SON-1010 uses Sonnet’s proprietary FHAB™ (Fully Human Albumin Binding) technology that leverages […] Read more

GreenLight Names Kimball Hall as Chief Operating Officer

GreenLight announced today the appointment of Kimball Hall as Chief Operating Officer, adding to the company’s executive leadership team. Ms. Hall will focus on the growth of GreenLight as the leading Partner Research Organization (PRO) for outsourced integrated gene to GMP services for large molecules and antibody drug conjugates.  She joins GreenLight from Genentech, a […] Read more

GreenLight offers integrated clinical translation of biologics with launch of ADC Cascade and Biologics Cascade

Cambridge, UK 07 October 2019 – GreenLight, the leading biologics target to GMP Partner Research Organisation, announced it has augmented its antibody drug conjugation (ADC) and biologics (including mono and bispecific antibodies) development services with the launch of ADC Cascade and Biologics Cascade. These ex-vivo platform approaches allow efficacy and safety studies against clinically characterized […] Read more

GreenLight announces successful technical transfer of Synaffix GlycoConnect™ Antibody Drug Conjugate (ADC) technology to enable use in client projects

San Diego, USA July 2019 – GreenLight, the global partner research organization, announced it has successfully completed a technology transfer and scalability evaluation using the Synaffix technologies of GlycoConnect™ (antibody conjugation) and HydraSpace™ (highly polar spacer). Familiarity with these Antibody-Drug Conjugate (ADC) technologies adds to GreenLight’s leadership in process development and GMP manufacturing of ADC […] Read more

GreenLight expands leadership team with Andrew Kraus as Chief Technology Officer and Philip Payne as Chief Commercial Officer

San Diego, USA , 21 June 2019 – GreenLight, the leading global biologics and ADC target partner research organization, announced it has appointed Andrew Kraus as Chief Technology Officer (CTO) and Philip Payne as Chief Commercial Officer (CCO). As CTO Mr. Kraus will implement advanced technology solutions to further enhance data integrity controls, regulatory compliance […] Read more

GreenLight announces 14-month cell line to phase 1 GMP service and appointment of Shahram Katousian as Head of biologics manufacturing

San Diego, USA, 3 June 2019 – GreenLight, the leading biotherapeutics target to GMP partner research organization (PRO) announced an accelerated program to IND.  This reduces timeline from stable pool to GMP down to 14 months. The timeline is achieved by use of single project team with experienced leadership, overlapping of operational activities, internal technology transfer […] Read more

GreenLight expands management team: appoints Campbell Bunce to the role of Chief Scientific Officer and Bo Adair as Senior Vice President Process and Operations

Cambridge, UK and San Diego, USA, 28 March 2019 – GreenLight, the leading global biologics target to GMP partner research organisation, announced it has appointed Dr Campbell Bunce as Chief Scientific Officer (CSO) and Bo Adair MBA as Senior Vice President Process and Operations. Dr Bunce joined GreenLight in November 2015 as SVP Scientific Operations […] Read more

GreenLight Announces New Fully Integrated Developability and Optimization Service to Improve Lead Selection and De-risk Biologic Cell Line Development

Cambridge, UK 21 March 2019 – GreenLight, the leading biologics target to GMP partner research organisation (PRO), announced its Cambridge UK site has brought together its extensive discovery, immunogenicity assessment, protein engineering, formulation, bioassay and analytical expertise to launch a developability assessment and optimization service to assist customers in selecting and developing the best lead candidate […] Read more

GreenLight and Lipum AB sign integrated CMC agreement to produce a novel biologic for autoimmune inflammatory diseases

  San Diego, USA, 19 March 2019 – GreenLight, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, a company developing treatments for chronic inflammatory diseases. GreenLight will support Lipum’s anti-BSSL antibody IND program to help develop a novel therapeutic option for […] Read more

Interested in our services? Get In Touch